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Metastatic Gastrointestinal Carcinoid Tumor with 
Unknown Primary Site
Peter S. Liang, B.S., and Kitt Shaffer, M.D., Ph.D.
Carcinoid tumors are rare and slow growing malignancies derived from enterochromaffin cells. Two-
thirds of carcinoid tumors arise in the gastrointestinal tract, and in 3% of these cases the primary site 
cannot be determined. Presenting symptoms depend on the location of the primary tumor but may be 
nonspecific, and in 13% of patients distant metastases are discovered on diagnosis. The classic carci-
noid syndrome occurs in less than 10% of cases and only after metastasis to the liver. We present a case 
of a young woman with a gastrointestinal carcinoid tumor of unknown site that had metastasized to 
the liver. We also provide a review of the current diagnostic modalities. Familiarity with the signs and 
symptoms of carcinoid tumors and the diagnostic techniques thereof may facilitate early detection and 
improved outcome.
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 Carcinoid tumors are rare and slow growing malignan-
cies that derive from neuroendocrine enterochromaffin 
cells, which are found in various regions of the body. Data 
from 13,715 patients compiled by the National Cancer 
Institute (NCI) over three series from 1950-1999 indicate 
that that 67% of carcinoid tumors arise from the gastro-
intestinal (GI) tract while another 25% are found in the 
bronchopulmonary system [1]. Although the majority 
of carcinoids derive from the gastrointestinal tract, they 
comprise only 2% of all GI maligancies [2]. Within the 
gastrointestinal tract, the three most common sites of 
carcinoid tumor occurrence are the ileum (21%), rectum 
(20%), and appendix (18%). In 3% of cases, the primary 
site of a digestive tract carcinoid tumor is unknown. In the 
most recent NCI series, distant metastases were found on 
diagnosis in 13% of all patients and 16% of patients with 
a primary lesion in the gastrointestinal tract. The overall 
5 year survival rate for all carcinoid tumors is 67%. The 
prognosis is expectedly worse for patients with distant 
metastases, with the 5 year survival rate dropping to 39%. 
The liver is the most common site of distant metastasis. 
The average age at diagnosis for all carcinoid tumors is 61 
years by the latest data, and there are notable differences 
depending on the primary site. Small bowel tumors have 
the latest age of diagnosis at 65 years, while the youngest 
diagnosed patients are those with appendiceal tumors, who 
have an average age of 49 years [1]. The classic “carcinoid 
syndrome,” in which patients present with flushing, diar-
rhea, and wheezing, occurs in less than 10% of cases [3]. 
Therefore the correct diagnosis relies on a combination of 
clinical signs, biochemical markers, and radiological stud-
ies. Radiological studies are used for both primary tumor 
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Figure 1B. Abdominal CT shows mesenteric (arrow) and 
retroperitoneal lymphadenopathy. There were no calcified 
mesenteric masses, radiating strands, or bowel wall thicken-
ing.Figure 1A. 21-year-old woman with metastatic carcinoid 
tumor.  Abdominal CT in liver window shows numerous 
small heterogeneous hypodense lesions in the liver, some 
with central enhancement (arrows). Most lesions have poorly 
demarcated borders.
localization and detection of metastases, which in turn 
determines the feasibility of various treatment modalities. 
We present a case of carcinoid tumor with an unknown 
primary site and liver metastasis in a young female.
 A 21-year-old woman presented to the emergency room 
with severe epigastric and right upper quadrant pain, 
nausea, and vomiting for one week. Prior to the onset of 
abdominal pain, she developed a diffuse erythematous 
petechial rash on her cheeks, arms, and abdomen as well as 
facial edema. The patient reported having chronic abdomi-
nal pain as a child, but the episodes never reached such 
intensity and were never accompanied by rash and edema. 
The patient also experienced a recent episode of night 
sweats and an intentional five-pound weight loss over the 
past few months. She was diagnosed with Type 1 diabetes 
mellitus at age five and reported poor glycemic control 
in the past week due to decreased appetite. On physi-
cal exam, the patient’s vital signs were stable and within 
normal limits. She was diffusely tender to palpation over 
the abdomen, especially in the right upper quadrant. Labo-
ratory studies revealed a borderline elevated white blood 
cell count and a normal hematocrit and platelet count. The 
complete metabolic panel was within normal limits except 
for a low serum glucose. Liver enzymes, amylase, lipase, 
and coagulation times were all normal. Urinalysis showed 
glucosuria.
 In the emergency room, CT imaging of the abdomen 
and pelvis was performed with oral and IV contrast. Nu-
merous heterogeneous hypodensities, many with central 
enhancement, were discovered throughout the liver. The 
lesions had poorly demarcated borders. Most of the lesions 
measured 1 cm or less in diameter, but several large masses 
measuring greater than 4 cm in diameter were present in 
both lobes (Fig. 1). Both retroperitoneal and mesenteric 
lymphadenopathy was also present. The left adnexa also 
appeared mildly enlarged. The pancreas, spleen, kidneys, 
adrenal glands, gall bladder, small bowel, appendix, and 
colon all appeared normal. The patient was admitted for 
further investigation of the liver lesions and glycemic con-
trol.
 On hospital day 1, a chest CT and abdominal ultra-
sound were performed. The chest CT was normal and 
did not reveal hilar or mediastinal lymphadenopathy. The 
abdominal ultrasound revealed numerous hypoechoic 
nodules in the liver that were consistent with the lesions 
found on CT (Fig. 2). An ultrasound-guided core biopsy 
was taken from a large mass in the left hepatic lobe. The 
final pathologic diagnosis was metastatic carcinoid tumor. 
Staining patterns suggested that the primary tumor was 
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Figure 2. Sagittal right upper quadrant sonogram shows 
numerous hypoechoic hepatic masses.
located in the colon, and somatostatin receptor scintigra-
phy (OctreoScan) was performed for tumor localization. 
Increased uptake was detected throughout the liver and in 
the region of the aorta that most likely corresponded to 
the retroperitoneal lymphadenopathy at 4 hours and 24 
hours post injection (Fig. 3). At 24 hours, there was also 
increased activity in the colon. There was no activity in the 
lungs. A capsule endoscopy was performed to assess small 
bowel involvement. A small, non-ulcerated bulge was visu-
alized in the mid-jejunum that may represent the primary 
tumor in the submucosa or a prominent intestinal fold 
(Fig. 4). Additional attempts to localize the primary lesion 
using upper endoscopy and colonoscopy were unsuccess-
ful. The patient developed severe headaches during her 
hospital course, and brain metastases were ruled out after a 
head CT.
 Other notable laboratory values during the hospital 
course included the following: an elevated urine 5-HIAA 
(161 mg/24 hr), elevated CA 19-9 antigen (62 units/mL), 
low cortisol (0.6 mcg/dL), and elevated gastrin (142 pg/
mL). Alpha fetoprotein, CEA, serum glucagon, and CA 
125 antigen were within normal range. Serology studies 
showed reactivated EBV and was negative for CMV, HIV, 
and Toxoplasma.
 The patient was not considered a surgical candidate due 
to her widespread metastatic disease, and further workup 
to definitively determine the primary tumor site was not 
conducted as it would not have altered the treatment plan. 
She was referred to a cancer center and has been enrolled 
in a clinical trial.
 Gastrointestinal carcinoids can present in various ways, 
depending on the site of the primary tumor and whether 
metastases are present. Carcinoids of the foregut can 
secrete substances such as 5-hydroxytryptophan (5-HTP), 
adrenocorticotropic hormone (ACTH), and histamine and 
cause an atypical carcinoid syndrome. This is less often as-
sociated with flushing than the classic carcinoid syndrome 
and typically presents with abdominal pain, diarrhea, 
and weight loss. Midgut carcinoids, which can secrete 
5-hydroxytryptamine (5-HT), kinins, prostaglandins, and 
substance P, manifest with the classic carcinoid syndrome 
after metastasis to the liver. Symptoms include flushing, 
diarrhea, cardiac valvular disease, wheezing, and pellagra. 
Carcinoids originating from the hindgut usually do not 
secrete 5-HT and therefore rarely present with symptoms 
of the carcinoid syndrome. The presence of other clinical 
findings, such as recurrent abdominal pain and hepatosple-
nomegaly, should also increase the suspicion for carcinoid 
tumor.
 A defining characteristic of enterochromaffin cells is 
their ability to secrete serotonin, and therefore the urinary 
measurement of the serotonin metabolite 5-HIAA is used 
in the laboratory diagnosis of carcinoids. The specificity of 
a 24 hour urinary 5-HIAA measurement for carcinoid tu-
mors is approximately 88%. Serum chromogranin A is the 
most sensitive biochemical marker for carcinoids, but be-
cause it is constitutively secreted by most neuroendocrine 
tumors, it has a lower specificity than urinary 5-HIAA.
 Nuclear medicine studies are the first option for primary 
tumor localization and detection of metastases. Somatosta-
tin receptor scintigraphy uses radiolabelled somatostatin 
analogues to bind and detect two somatostatin recep-
tor subtypes (2 and 5) that are expressed by 70-90% of 
carcinoid tumors [4]. 111-Indium-DTPA-octreotide is 
the most commonly used radioligand and has a sensitivity 
of 80-90% irrespective of the primary tumor site [5,6]. 
Positron emission tomography (PET) using 18-F-FDG has 
been shown to have a low sensitivity in carcinoid detec-
tion [7]. However, PET studies using 11-C-5HTP [8] and 
68-Ga-octreotide [9] tracers have demonstrated higher 
detection rates with than with octreotide scintigraphy. 
Currently, PET remains an investigational technique for 
carcinoid detection. Metaiodobenzylguanidine (MIBG) 
labelled with iodine-123 or iodine-131 is the oldest of the 
nuclear medicine methods. It is highly specific for neu-
roendocrine tumors [10] but has a lower sensitivity than 
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somatostatin receptor scintigraphy [11]. 111-In-DTPA-
octreotide is recommended as the study of choice for imag-
ing carcinoid tumors [12].
 If nuclear medicine studies fail to localize the primary 
tumor, as was the case for our patient, direct visualization 
with endoscopy and endoscopic ultrasound may be at-
tempted. Upper endoscopy and colonoscopy are both op-
erator-dependent procedures that are limited by anatomic 
boundaries. Case reports suggest that capsule endoscopy 
has a role in the detection of small bowel lesions, which 
are poorly visualized by esophagogastroduodenoscopy 
(EGD) [13,14]. No modality has been established as the 
“gold standard” diagnostic study for small bowel tumors. 
Push enteroscopy is also limited in reach and cannot 
extend beyond the proximal jejunum [15]. In a random-
ized control trial, capsule endoscopy was shown to have 
a higher detection rate but a lower specificity than push 
enteroscopy [16]. A prospective study comparing capsule 
endoscopy with octreotide scintigraphy concluded that the 
two modalities have similar diagnostic yields, but it is im-
possible to differentiate between intestinal and mesenteric 
localization on scintigraphy [17]. The main disadvantage 
of capsule endoscopy is the inability to control the angle 
or duration of visualization of any area of interest. Since 
findings may only appear in a single frame of the recorded 
video, it is often difficult to differentiate between a normal 
prominent plica and an abnormality. No data exists on 
the false-positive rate for capsule endoscopic diagnosis of 
small bowel tumors, but a colonic polyp study showed 
that false-positive findings based on expert interpretation 
of capsule endoscopy were present in 33% of cases when 
compared to conventional colonoscopy [18]. Endoscopic 
ultrasound is highly sensitive in detecting foregut carici-
noids and can detect small lesions measuring 2-3 mm, but 
again its usefulness is limited by the mechanical difficulty 
of traversing the small bowel [19]. In our case, the capsule 
endoscopy captured a mid-jejunal bulge, but the notion of 
a small bowel primary lesion was not supported by either 
the octreotide scintigraphy or the liver specimen staining 
pattern, which pointed to the colon as the likely primary 
site. Push enteroscopy and endoscopic ultrasound were 
not performed, but they would have been unlikely to yield 
additional information given the length limitation of the 
endoscopes. The significance of the small bowel finding 
visualized on capsule endoscopy could not be determined 
in the absence of histological evidence.
 Several aspects of this case are unusual and notewor-
thy. First, despite a thorough localization workup with 
Figure 3A. At 4 hours after injection, there is increased up-
take in the liver and retroperitoneal lymph nodes. There is no 
increased uptake in the lungs.
Figure 3B. Octreotide scintigraphy. At 24 hours after injec-
tion, there is increased uptake in the liver, retroperitoneal 
lymph nodes, and the colon. There is no increased uptake in 
the lungs.
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111-In-labelled octreotide scintigraphy, upper endoscopy, 
colonoscopy, and capsule endoscopy, the primary tumor 
site was not determined. Furthermore, the pathologic and 
capsule endoscopic evidence point to different regions as 
the likely site of origin. Whereas the tissue staining pattern 
suggests a colonic origin, the capsule endoscopy suggests 
a small bowel origin for the primary tumor. The primary 
lesion remains unknown in only 3% of gastrointestinal 
carcinoid cases. A second noteworthy aspect of the case 
is the patient’s age, which at 21 years is far less than the 
average age of diagnosis of 61 years. The youngest patient 
in the literature with a diagnosis of carcinoid tumor is a 
3 year old with an appendiceal carcinoid, which is a well 
known condition in the pediatric population [21]. Our re-
view of the literature finds that the youngest patient with a 
non-appendiceal GI carcinoid is 12 years of age [22]. Our 
patient is likely among the youngest group of patients with 
metastatic carcinoid tumor, although the lack of analysis 
with regard to age of incidence in the literature makes this 
difficult to substantiate.
 Carcinoids are rare and slow-growing tumors which do 
not usually present with the classically described carcinoid 
syndrome. In order to improve survival, early diagnosis 
before metastatic spread of disease is necessary and the 
clinician should consider carcinoid tumors in the differen-
Figure 4. Capsule endoscopy images taken 6 seconds apart show a bulge protruding into the gastrointestinal lumen at the level 
of the mid-jejunum. This may represent the primary tumor in the submucosa or a normal prominent intestinal fold.
tial diagnosis of nonspecific symptoms such as recurrent 
abdominal pain and hepatosplenomegaly. Somatostatin 
receptor scintigraphy with 111-In-DTPA-octreotide is cur-
rently the diagnostic study of choice for carcinoid tumors, 
and new PET techniques hold promise for increased rates 
of detection in the future.
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